Search
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalPrimary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation. … The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]
Categories: Bile Acids and Salts, Bile and Liver TherapyBimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigational[A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment … [L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsRelatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001] … [A246160] and melanoma.
Categories: nivolumab and relatlimab, Amino Acids, Peptides, and ProteinsEthylmorphine
go.drugbank.com/drugs/DB01466IllicitInvestigationalIt is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products). … A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function.
Categories: Cough and Cold Preparations, Opium Alkaloids and DerivativesIsocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.
Dichloralphenazone
go.drugbank.com/drugs/DB01495ApprovedIllicitIt is a US Schedule IV drug and its clinical use is limited. … It is typically found in combination products Nodolor and Midrin containing [isometheptene] and [acetaminophen] used for the relief of tension and vascular headaches.
Mixtures: Isometheptene Mucate, Dichloralphenazone, and Acetaminophen, Isometheptene Mucate, Dichloralphenazone, and AcetaminophenCategories: Hypnotics and SedativesZolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923] … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsWU-CART-007
go.drugbank.com/drugs/DB18617InvestigationalWU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.
Synonyms: an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7AAV9/MFSD8
go.drugbank.com/drugs/DB18616ExperimentalIt is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8 … AAV9/MFSD8 is a gene therapy developed by Neurogene Inc.
Synonyms: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8